David Li

3 weeks ago | devblogs.microsoft.com | David Li

Visual Studio 2022 version 17.14 comes with quality-of-life improvements to its C++ Build Insights integration that will make it easier for you to navigate large multi-project traces and handle long file names for your build inputs and artifacts. What is C++ Build Insights? C++ Build Insights is a powerful tool that lets you visualize and optimize the build process of your C++ projects.

1 month ago | businessandamerica.com | David Li

A Fox News Channel analyst fainted on air Thursday night in mid-sentence of her harsh critique of the Biden administration, forcing a show host to awkwardly try going to another guest before heading to break. Camryn Kinsey was criticizing former President Joe Biden and then-Vice President Kamala Harris when she started slowing down, stopped speaking altogether and suddenly toppled over to her left. “They have to rewrite history because they had a failed campaign.

1 month ago | wfla.com | David Li |Jay Blackman

by: David K. Li, Jay Blackman Posted: May 8, 2025 / 01:54 PM EDT Updated: May 8, 2025 / 01:54 PM EDT Related video: How AI technology could enhance air traffic controlThe FAA will embark on an ambitious three-year plan to modernize America’s air traffic control systems and phase out the “outdated technologies that are unable to meet” modern demands, officials said Thursday.

2 months ago | onlinelibrary.wiley.com | David Li |Justin Weinkauf |Alim Hirji |Jason Weatherald

BLAD baseline lung allograft dysfunction CI confidence interval CLAD chronic lung allograft dysfunction FEV1 forced expiratory volume in 1 second FVC forced vital capacity HR hazard ratio OR odds ratio PGD primary graft dysfunction 1 Introduction The ongoing opioid crisis, increased legal access to cannabis, and reduction in organ donation during the COVID-19 pandemic have all highlighted organ utilization from donors with a prior history of substance abuse as an important area of study, as...

2 months ago | timmermanreport.com | David Li |Luke Timmerman

We have entered a new era in biotech.  Turmoil at the FDA has introduced new uncertainty. NIH funding cuts and grant delays have led to academic institutions to hold off on job offers to young scientists. The Trump Administration’s reset of trade relations with the world caused a financial market meltdown, and wild rebound. All of these things are contributing factors making the biotech downturn longer and more intense than almost anybody imagined.